Imatinib (STI571，伊马替尼) - 仅供科研 | 酪氨酸激酶抑制剂 | MCE
Imatinib (STI571) 是一种口服生物可用的酪氨酸激酶抑制剂，可选择性抑制 BCR/ABL，v-Abl，PDGFR，c-kit 激酶活性。Imatinib (STI571) 靠近 ATP 结合位点结合，将其锁定在封闭或 …
Glivec (STI571, imatinib), a rationally developed, targeted ... - Nature
2002年7月1日 · The best compound from this series was a methylpiperazine derivative that was originally named STI571 (imatinib, now known as Glivec or Gleevec), which was selected as …
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment ...
STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have …
STI571 (Gleevec™) as a paradigm for cancer therapy
2002年4月1日 · STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This …
STI571, a tyrosine kinase inhibitor for the treatment of chronic ...
STI571 (formerly CGP57148B), is an Abl-specific tyrosine kinase inhibitor that in preclinical studies selectively kills Bcr-Abl-containing cells in vitro and in vivo. The results of clinical …
STI-571: an anticancer protein-tyrosine kinase inhibitor
2003年10月3日 · STI-571 (imatinib, Gleevec, Glivec, CGP 57148) is an inhibitor of the Abl group of protein-tyrosine kinases. One of these enzymes, the Bcr-Abl oncoprotein, results from the …
STI-571: an anticancer protein-tyrosine kinase inhibitor
2003年10月3日 · STI-571 (imatinib, Gleevec, Glivec, CGP 57148) is an inhibitor of the Abl group of protein-tyrosine kinases. One of these enzymes, the Bcr-Abl oncoprotein, results from the …
STI571: targeting BCR-ABL as therapy for CML - PubMed
Therapeutic agent STI571 (signal transduction inhibitor number 571) is a rationally developed, potent, and selective inhibitor for abl tyrosine kinases, including bcr-abl, as well c-kit and the …
伊马替尼 (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂 …
2024年9月3日 · 体外：Imatinib (STI571) 抑制 c-Kit 自磷酸化、MAPK 激活和 Akt 激活，而不改变 c-kit、MAPK 或 Akt 的总蛋白水平。对这些作用产生 50% 抑制的浓度约为 100 nM [1] 。 伊马 …
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the
STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have …